Hints and tips:
Related Special Reports
...Merck’s Covid-19 antiviral pill failed to show it can lower the risks of hospitalisation and death among adults at higher risk from the disease, according to the results of a pivotal clinical trial in the...
...At the mid-level, a cashmere style in a muted shade from Sheep Inc, John Smedley or — my favourite — Begg x Co will quickly become a staple of your wardrobe....
...Dean Li, president of Merck’s research laboratories, praised the UK’s scientific talent and expertise, hoping that the investment in King’s Cross will help researchers at MSD, known as Merck in the US, work...
...A person familiar with the process said Merck “understood there was no hope . . . [Lagevrio] is a bit burnt”....
...But future demand would suffer unless Merck was able to provide better clinical data....
...The new rules give the federal government the power to negotiate lower prices for some of the most expensive prescription drugs produced by Pfizer, Merck and other pharma companies purchased by Medicare,...
...Molnupiravir, marketed by Merck and co-developed with US biotech group Ridgeback Biotherapeutics, works by inducing small mutations in the virus itself....
...He said Merck’s claim that the reforms were an “extortion” was accurate....
...When Ken Frazier, another law school friend, was CEO of Merck and facing criticism for refusing to cut research budgets, Ogunlesi reassured him he was doing the right thing....
...Merck is either optimistic or desperate if it is willing to pay $5bn more than Prometheus’ valuation three days ago. But it has the funds....
...Under the terms of the transaction Merck is acquiring Prometheus through a subsidiary....
...“We are encouraged by these findings from Panoramic,” said Merck, which is known as MSD outside North America....
...“When appropriate, Merck seek to protect its additional innovation,” he added. Merck said it continued to point to late 2028 as the most likely timeframe for biosimilar entry into the market....
...Weber is a paid consultant for Merck and Moderna....
...Merck’s Keytruda now tackles 18 tumour types and is set to be the world’s top-selling medicine next year, according to Evaluate Vantage....
...Chief financial officer Caroline Litchfield said the company operates with the highest “ethics and integrity in absolutely everything we do” and is continuing to co-operate with the Senate finance committee...
...SeaGen lacks a permanent chief executive after co-founder Clay Siegall stepped down in May, so Merck may be tempted to push ahead....
...Merck & Co is in talks to buy the cancer biotechnology company SeaGen for about $40bn, according to two people familiar with the matter....
...“Pfizer is very good at selling but historically not renowned as having the R&D engine of a Merck or Lilly....
...Both Roche’s gantenerumab and lecanemab, co-developed by Eisai and Biogen, are monoclonal antibody treatments based on the hypothesis....
...Merck said it had supply agreements with over 30 countries....
...This was sharply lower than the 50 per cent efficacy that Merck announced in October from a preliminary analysis of the data....
...Molnupiravir, co-developed with Ridgeback Biotherapeutics and also known as Lagevrio, has been approved for use in the UK. European regulators are also reviewing it....
...Last week, Merck said the treatment was less effective than it had thought....
...The Korean Wave opens September 24, V&A ‘Make, Break, Remix: The Rise of K-Style’ by Fiona Bae, (Thames & Hudson), will be published in the UK & Ireland on 22 September 2022...
International Edition